MetaCap

Quantum Cyber N.V. (QUCY) vs Spero Therapeutics (SPRO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Quantum Cyber N.V. (QUCY) has outperformed Spero Therapeutics (SPRO) over the past year, losing 48.7% versus a loss of 67.9%. Over five years, QUCY leads with a -94.8% price change compared with -95.1% for SPRO. Quantum Cyber N.V. is the larger company by market cap ($44.7 million vs $43.2 million), about 1.0 times the size, while Spero Therapeutics is growing revenue faster (+39.2% vs -39.9%).

Spero Therapeutics converts more of its revenue into profit, with a net margin of 12.8% versus -3018.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

QUCY-48.75%SPRO-67.88%
+273%+94%-84%
Nov 21, 20251 yearNov 20, 2026
QUCY-94.78%SPRO-95.50%
+197%+43%-112%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

QUCY versus SPRO key metrics
MetricQUCYSPRO
Share price$0.512$0.742
Market cap$44.67M$43.23M
1-day change-7.25%-10.20%
YTD return-54.29%-68.15%
1-year return-48.75%-67.88%
5-year return-94.80%-95.09%
EPS (TTM)$-2.27$-0.50
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$537.08K$66.80M
Revenue growth (YoY)-39.92%+39.24%
Net income (latest FY)$-16.21M$8.57M
Gross margin72.58%—
Operating margin-3004.97%9.45%
Net margin-3018.31%12.83%
52-week high$4.93$3.08
52-week low$0.30$0.73
Distance from 52-week high-89.61%-75.91%
Analyst consensusnonenone
Avg. price target upside+1657.81%+573.85%
Average volume528.02K530.46K
Shares outstanding87.24M58.26M
Employees1025
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • QUCY has outperformed SPRO by 19.1 percentage points over the past year.
  • Spero Therapeutics is more profitable, keeping 12.8 cents of every revenue dollar as net income versus -3018.3 cents for Quantum Cyber N.V..
  • Spero Therapeutics grew revenue faster in its latest fiscal year (+39.24% vs -39.92%).

About Quantum Cyber N.V.

QUCY stock →

Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

About Spero Therapeutics

SPRO stock →

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

QUCY vs SPRO FAQ

Which is bigger, Quantum Cyber N.V. or Spero Therapeutics?

Quantum Cyber N.V. (QUCY) is larger, with a market capitalization of $44.67M compared with $43.23M for Spero Therapeutics (SPRO).

Which stock has performed better over the past year, QUCY or SPRO?

QUCY returned -48.75% over the past 12 months, compared with -67.88% for SPRO (price return, excluding dividends). Past performance does not predict future results.

Are Quantum Cyber N.V. and Spero Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons